

## RESEARCH ARTICLE

# Electrophysiological analysis of subclinical peripheral neuropathy in cases with type I diabetes mellitus

Santosh V Chidri<sup>1</sup>, Vidya G<sup>2</sup>

<sup>1</sup>Department of Physiology, Kamineni Academy of Medical Sciences and Research Center, Hyderabad, Telangana, India, <sup>2</sup>Department of Physiology, Government Medical College, Nalgonda, Telangana, India

Correspondence to: Santosh V Chidri, E-mail: santosh.chidri@gmail.com

Received: July 13, 2020; Accepted: August 10, 2020

### ABSTRACT

**Background:** Diabetic neuropathy termed as an existence of peripheral nerve dysfunction in cases with diabetes mellitus (DM). Type 1 DM (T1DM) is commonly associated with diabetic neuropathy. Nerve conduction assessment plays key role evaluate the electrophysiological response of the nervous system to different stimuli. **Aim and Objective:** This study was designed to assess the subclinical central and peripheral neuropathy in cases with T1DM. **Materials and Methods:** A total of 120 cases diagnosed clinically with T1DM with no history of neuropathy were recruited. Demographic details, clinical history, and details of glycemic status were recorded from all the study participants. Nerve conduction study in sural nerve and visual evoked potentials were assessed. **Results:** The mean difference of sural nerve conduction velocity and amplitude on the right leg and left leg was statistically significant between diabetic cases and control subjects ( $P < 0.005$ ). The mean difference of P<sub>100</sub> latency and amplitude on the right leg and left leg was statistically significant between diabetic cases and control subjects ( $P < 0.005$ ). **Conclusion:** Electrophysiological analysis is the most reliable and non-invasive modalities in the early diagnosis of changes in optic pathways and peripheral sensory nerves in T1DM. Nerve conduction assessment is considered as a gold standard technique in the quick diagnosis of diabetic neuropathy.


**KEY WORDS:** Nerve Conduction Velocity; Sensory Nerve; Visual Evoked Potential; Type 1 Diabetes Mellitus

### INTRODUCTION

Diabetic peripheral neuropathy is a heterogeneous group of nerve disorders and is a major clinical complication in cases with type 1 diabetes mellitus (T1DM).<sup>[1]</sup> It is affecting 30% of cases with DM and prevalence in children and adults ranges between 57% and 7%, respectively. Disease prevalence is influenced by dyslipidemia, smoking, obesity, uncontrolled glucose levels, and duration of disease.<sup>[2-4]</sup> Around 60–70% of

cases with DM have some form of neuropathy. If neuropathy is central, it influences visual pathway or else peripheral that it shows the impact on peripheral nerves.<sup>[5]</sup> Nerve conduction assessment and visual evoked potentials are non-invasive procedures to evaluate the electrophysiological response of the nervous system to different stimuli.<sup>[6]</sup>

Nerve conduction studies, especially to sensory nerves, help to evaluate the deformity in peripheral nerves. The involvement of sensory nerves leads to loss of sensation over affected foot and develops foot ulcers. The nerve conduction studies in the nerves of limbs were highly correlated. Assessment of motor and sensory nerve conduction function can, therefore, be restricted to the most sensitive test. Peripheral neuropathy and autonomic neuropathy are stronger than the traditional risk factors for future mortality.<sup>[7]</sup>

Access this article online	
Website: <a href="http://www.njppp.com">www.njppp.com</a>	Quick Response code 
DOI: 10.5455/njppp.2020.10.07186202010082020	

National Journal of Physiology, Pharmacy and Pharmacology Online 2020. © 2020 Santosh V Chidri and Vidya G. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Still, there is a lack of the literature on the subclinical neuropathy in the early adults and adult age group. With reference to the above literature, this study was designed to assess the subclinical central and peripheral neuropathy in cases with T1DM.

## MATERIALS AND METHODS

In the present prospective observational study, 120 cases with T1DM attending the outpatient department of Kamineni Academy of Medical sciences and Research Centre, Hyderabad, between April 2019 and January 2020, between 21 and 40 years, were recruited. A total of 30 age- and sex-matched control subject were considered. Cases diagnosed with type 1 diabetes for a period not <5 years with no history of neuropathy were included in the study. Cases with hypertension, type 2 diabetes, diabetic retinopathy, traumatic neuropathy, and other ocular complications were excluded from the study. Informed consent was obtained from all the study participants and the study protocol was approved by the Institutional Ethics Committee (No: KAMSR/IEC/12/49).

All cases were undergone with a detailed clinical and neurological examination. Demographic details, clinical history, and details of glycemic status were recorded from all the study participants. Nerve conduction study in sural nerve and visual evoked potentials were assessed using standardized and computerized nerve conduction test equipment in the neurology outpatient department. The collected data were compared between cases and control subjects. For these analyses, data analysis was conducted using SPSS statistical software.

## RESULTS

The observations made in the present study are described in Tables 1–3.

## DISCUSSION

Subclinical diabetic peripheral neuropathy is a common clinical condition in T1DM than T2DM.<sup>[8-10]</sup> Diagnosis is difficult due to its asymptomatic nature. Therefore, early diagnosis is important to prevent associated complications

and disabilities. The ideal diagnosis of diabetic peripheral neuropathy depends on electrophysiological changes and clinical observations. Diabetic peripheral neuropathy is associated with nerve dysfunctions. Nerve conduction studies help in the diagnosis of subclinical diabetic peripheral neuropathy.<sup>[11]</sup> This study was designed to assess the subclinical central and peripheral neuropathy in cases with T1DM. A total of 120 cases and 30 age- and sex-matched control subjects between the age group 20 and 45 years were recruited. Based on the onset duration of type 1 diabetes, cases were allocated into three groups, that is, 0–5 years, 6–10 years, and 11–15 years. The mean age of T1DM in disease duration 0–5 years was 24.21, in 6–10 years was 26.38, and in 11–15 years was 37.84. The mean age in the control subjects was 25.02 years. The mean difference in age between cases and controls was statistically not significant ( $P > 0.005$ ). The sural nerve conduction velocity in the right leg was 50.32 m/s in 0–5 years diabetic group, 45.27 m/s in 6–10 years diabetic group, and 39.81 m/s in 11–15 years diabetic group. The sural nerve conduction velocity in the left leg was 50.18 m/s in 0–5 years diabetic group, 46.02 m/s in 6–10 years diabetic group, and 38.26 m/s in 11–15 years diabetic group. The mean difference of sural nerve conduction velocity and amplitude on the right leg and left leg was statistically significant between diabetic cases and control subjects ( $P < 0.005$ ) [Table 2]. The mean difference of  $P_{100}$  latency and amplitude on the right leg and left leg was statistically significant between diabetic cases and control subjects ( $P < 0.005$ ) [Table 2]. The mean BMI in three groups of T1DM and controls was 23.20, 23.38, 23.89, and 23.11, respectively. The mean difference in BMI was statistically not significant ( $P > 0.005$ ) [Table 1]. The mean difference of fasting blood glucose and postprandial blood glucose was statistically significant between cases and controls ( $P < 0.005$ ) [Table 1].

A study by Toopchizadeh *et al.* included 40 cases with a mean age 12.73 years and mean duration of diabetes was 6.63 years.<sup>[8]</sup> A study by Mohamed *et al.* included 50 children with T1DM with mean age 10.5 years. Among the study, 12% of cases were diagnosed with diabetic neuropathy.<sup>[12]</sup> A study by Prakash *et al.* noticed abnormal nerve conduction in 20 cases. Among the cases, 2 had diabetes <5 years and 18 had diabetes >5 years.<sup>[11]</sup> A study by Al-Taweel *et al.* found that the frequency of subclinical neuropathy was 61.7% in T1DM cases and disease frequency was high in cases with disease

**Table 1: Demographic data and glycemic status of the study participants**

Parameters	T1DM (n=120) (Mean±SD)			Controls (n=30) (Mean±SD)	P-value
	0–5 years	6–10 years	11–15 years		
Age (In years)	24.21±4.18	26.38±4.07	37.84±3.63	25.02±2.89	0.033
Sex (Male:Female)	19:15	22:16	24:24	15:15	-
BMI	23.20±1.65	23.38±1.23	23.89±2.61	23.11±1.98	0.448
Fasting blood glucose	93.78±5.32	91.28±7.82	93.09±9.55	86.22±3.74	0.005
PPPG (mg/dl)	299±86.2	309±92.69	331±93.54	94±10.84	0.005

T1DM: Type 1 diabetes mellitus

**Table 2: Comparison of sural NCV and amplitude in the right and left leg**

Parameters	T1DM (n=120) (Mean±SD)			Controls (n=30) (Mean±SD)	P-value
	0–5 years	6–10 years	11–15 years		
Right leg					
NCV (m/s)	50.32±0.58	45.27±0.65	39.81±0.68	52.29±0.52	<0.005*
Amplitude (µv)	16.16±0.44	13.98±0.62	11.33±0.23	18.08±0.35	<0.005*
Left leg					
NCV (m/s)	50.18±0.59	46.02±0.74	38.26±0.43	51.37±0.27	<0.005*
Amplitude (µv)	16.38±0.55	14.01±0.48	11.85±0.59	18.16±0.43	<0.005*

NCV: Nerve conduction velocity, T1DM: Type 1 diabetes mellitus

**Table 3: Comparison of P<sub>100</sub> latency and amplitude between in the right and left eye**

Parameters	T1DM (n=120) (Mean±SD)			Controls (n=30) (Mean±SD)	P-value
	0–5 years	6–10 years	11–15 years		
Right eye					
P <sub>100</sub> latency (ms)	103.26±0.58	105.37±0.62	106.85±0.63	98.86±0.522	<0.005*
Amplitude (µv)	6.94±0.571	5.28±0.502	5.26±0.496	8.35±0.418	<0.005*
Left eye					
P100 latency (ms)	103.48±0.21	108.25±0.48	111.39±0.45	98.92±0.57	<0.005*
Amplitude (µv)	6.82±0.54	5.22±0.77	3.18±0.60	7.58±0.61	<0.005*

T1DM: Type 1 diabetes mellitus

duration >5 years.<sup>[13]</sup> Based on the nerve conduction studies in 57% of cases, Nelson *et al.* found diabetic neuropathy with a disease duration of <5 years.<sup>[14]</sup> A study by Moser *et al.* diagnosed 11% of cases as diabetic peripheral neuropathy by nerve conduction analysis.<sup>[15]</sup> A study by Amer *et al.* found that about 59% of cases had diabetic neuropathy as diagnosed by nerve conduction assessment.<sup>[16]</sup> A study by Parkhad and Palve on 100 diabetic cases found that the nerve conduction velocity progressively decreased from control subjects (49.0 ± 3.9) to diabetic cases with controlled glycemic status (47.2 ± 2.8) to uncontrolled glycemic status (45.3 ± 3.1).<sup>[17]</sup>

Studies suggest that routine assessment of nerve conduction velocity in cases with T1DM is beneficial for early diagnosis of disease-associated complications.<sup>[18]</sup> In this study, demographic factors have no significant relation with the occurrence of diabetic neuropathy. The level of glycemic index was significantly associated with diabetic neuropathy. This study has a limitation with a minimal number of participants. Cases with T1DM shown less interest to participate in the study because nerve conduction studies were painful.

## CONCLUSION

The results of this study conclude that the assessment of routine nerve conduction velocity is beneficial in the evaluation of subclinical diabetic neuropathy. The electrophysiological analysis is the most reliable and non-invasive modalities in the early diagnosis of changes in optic pathways and

peripheral sensory nerves in T1DM. Nerve conduction assessment is considered as a gold standard technique in the quick diagnosis of diabetic neuropathy.

## REFERENCES

1. Mah JK, Pacaud D. Diabetic neuropathy in children. *Handb Clin Neurol* 2014;126:123-43.
2. Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D, editors. *Textbook of Diabetic Neuropathy*. Stuttgart, New York: Thieme; 2003. p. 64-82.
3. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. *Am Fam Physician* 2005;71:2123-8.
4. Michels A, Zhang L, Khadra A, Kushner JA, Redondo MJ, Pietropaolo M. Prediction and prevention of Type 1 diabetes: Update on success of prediction and struggles at prevention. *Pediatr Diabetes* 2015;16:465-84.
5. Jaiswal M, Divers J, Dabelea D, Isom S, Bell RA, Martin CL, *et al.* Prevalence of and risk factors for diabetic peripheral neuropathy in youth with Type 1 and Type 2 diabetes: SEARCH for diabetes in youth study. *Diabetes Care* 2017;40:1226-32.
6. Diana K. Trials in prevention of Type 1 diabetes: Current and future. *Can J Diabetes* 2014;38:284.
7. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH, *et al.* The EURODIAB Prospective Complications Study Group. The relationship between risk factors and mortality in Type 1 diabetic patients in Europe, the EURODIAB prospective complications study (PCS). *Diabetes Care* 2008;31:1360-6.
8. Toopchizadeh V, Shiva S, Khiabani NY, Ghergherechi R. Electrophysiologic pattern and prevalence of subclinical

- peripheral neuropathy in children and adolescents with Type I diabetes mellitus in Iran. *Saudi Med J* 2016;37:299-303.
9. Spallone V, Morganti R, D'Amato C, Cacciotti L, Fedele T, Maiello MR, *et al.* Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. *Eur J Pain* 2011;15:153-60.
  10. Gill HK, Yadav SB, Ramesh V, Bhatia E. A prospective study of prevalence and association of peripheral neuropathy in Indian patients with newly diagnosed Type 2 diabetes mellitus. *J Postgrad Med* 2014;60:270-5.
  11. Prakash G, Vijayaraju D, Manimala M, Angamuthu VJ, Krishnan M, Sengottuvelu S, *et al.* Prevalence of subclinical peripheral neuropathy by nerve conduction study in patients with Type 1 diabetes mellitus. *J Evid Based Med Healthc* 2019;6:2339-42.
  12. Mohamed MM, Ali RA, Hamdoon MN. Frequency and determinants of peripheral neuropathy in diabetic children in Sohag, Egypt. *J Behav Brain Sci* 2019;9:184-94.
  13. Al-Taweel YA, Fahmi RM, Shehta N, Elserafy TS, Allam HM, Elsaid AH. Frequency and determinants of subclinical neuropathy in Type 1 diabetes mellitus. *Egypt J Neurol Psychiatry Neurosurg* 2017;53:232-7.
  14. Nelson D, Mah JK, Adams C, Hui S, Crawford S, Darwish H, *et al.* Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with Type 1 Diabetes. *Pediatric Diabetes* 2006;7:305-10.
  15. Moser JT, Langdon DR, Finkel RS, Ratcliffe SJ, Foley LR, Andrews-Rearson ML, *et al.* The evaluation of peripheral neuropathy in youth with Type 1 diabetes. *Diabetes Res Clin Pract* 2013;100:36.
  16. Amer M, Kamal H, Siam A. Study of peripheral neuropathy in children with Type 1 diabetes mellitus at Zagazig university hospitals. *Zagazig Univ Med J* 2019;25:116-25.
  17. Parkhad SB, Palve SB. Early diagnosis of neuropathy in diabetic patients using nerve conduction studies. *Natl J Physiol Pharm Pharmacol* 2014;4:158-60.
  18. Holiner I, Haslinger V, Lutschg J, Muller G, Barbarini DS, Fussenegger J, *et al.* Validity of the neurological examination in diagnosing diabetic peripheral neuropathy. *Pediatric Neurol* 2013;49:171-7.

**How to cite this article:** Chidri SV, Vidya G. Electrophysiological analysis of subclinical peripheral neuropathy in cases with type I diabetes mellitus. *Natl J Physiol Pharm Pharmacol* 2020;10(12):1072-1075.

**Source of Support:** Nil, **Conflicts of Interest:** None declared.